vs
Guardant Health, Inc.（GH）与RadNet, Inc.（RDNT）财务数据对比。点击上方公司名可切换其他公司
RadNet, Inc.的季度营收约是Guardant Health, Inc.的1.9倍（$547.7M vs $281.3M）。RadNet, Inc.净利率更高（-0.1% vs -45.7%，领先45.6%）。Guardant Health, Inc.同比增速更快（39.4% vs 14.8%）。过去两年Guardant Health, Inc.的营收复合增速更高（29.2% vs 12.6%）
Guardant Health, Inc.是总部位于美国加利福尼亚州帕洛阿尔托的生物技术企业，由Helmy Eltoukhy与AmirAli Talasaz联合创立，目前二人共同出任公司首席执行官，统筹公司战略规划与日常运营管理工作。
RadNet是美国领先的放射医疗服务企业，总部位于加利福尼亚州洛杉矶，是美国规模最大的独立固定地址诊断影像中心运营商，按网点数量及年度影像业务收入计均居行业首位。截至2025年，该公司在全美8个州持有或运营超400家影像中心，提供门诊诊断影像服务。
GH vs RDNT — 直观对比
营收规模更大
RDNT
是对方的1.9倍
$281.3M
营收增速更快
GH
高出24.6%
14.8%
净利率更高
RDNT
高出45.6%
-45.7%
两年增速更快
GH
近两年复合增速
12.6%
损益表 — Q4 2025 vs Q4 2025
| 指标 | | |
|---|---|---|
| 营收 | $281.3M | $547.7M |
| 净利润 | $-128.5M | $-597.0K |
| 毛利率 | 64.6% | — |
| 营业利润率 | -43.0% | 5.1% |
| 净利率 | -45.7% | -0.1% |
| 营收同比 | 39.4% | 14.8% |
| 净利润同比 | -15.8% | -111.2% |
| 每股收益（稀释后） | $-1.01 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GHRDNT
| Q4 25 | $281.3M | $547.7M | ||
| Q3 25 | $265.2M | $522.9M | ||
| Q2 25 | $232.1M | $498.2M | ||
| Q1 25 | $203.5M | $471.4M | ||
| Q4 24 | $201.8M | $477.1M | ||
| Q3 24 | $191.5M | $461.1M | ||
| Q2 24 | $177.2M | $459.7M | ||
| Q1 24 | $168.5M | $431.7M |
净利润GHRDNT
| Q4 25 | $-128.5M | $-597.0K | ||
| Q3 25 | $-92.7M | $5.4M | ||
| Q2 25 | $-99.9M | $14.5M | ||
| Q1 25 | $-95.2M | $-37.9M | ||
| Q4 24 | $-111.0M | $5.3M | ||
| Q3 24 | $-107.8M | $3.2M | ||
| Q2 24 | $-102.6M | $-3.0M | ||
| Q1 24 | $-115.0M | $-2.8M |
毛利率GHRDNT
| Q4 25 | 64.6% | — | ||
| Q3 25 | 64.7% | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | 63.3% | — | ||
| Q4 24 | 61.6% | — | ||
| Q3 24 | 61.1% | — | ||
| Q2 24 | 59.1% | — | ||
| Q1 24 | 61.2% | — |
营业利润率GHRDNT
| Q4 25 | -43.0% | 5.1% | ||
| Q3 25 | -37.3% | 5.2% | ||
| Q2 25 | -45.9% | 6.2% | ||
| Q1 25 | -54.6% | -5.1% | ||
| Q4 24 | -62.4% | 5.1% | ||
| Q3 24 | -61.3% | 7.4% | ||
| Q2 24 | -56.8% | 7.6% | ||
| Q1 24 | -59.2% | 2.6% |
净利率GHRDNT
| Q4 25 | -45.7% | -0.1% | ||
| Q3 25 | -35.0% | 1.0% | ||
| Q2 25 | -43.0% | 2.9% | ||
| Q1 25 | -46.8% | -8.0% | ||
| Q4 24 | -55.0% | 1.1% | ||
| Q3 24 | -56.3% | 0.7% | ||
| Q2 24 | -57.9% | -0.6% | ||
| Q1 24 | -68.2% | -0.6% |
每股收益（稀释后）GHRDNT
| Q4 25 | $-1.01 | $0.00 | ||
| Q3 25 | $-0.74 | $0.07 | ||
| Q2 25 | $-0.80 | $0.19 | ||
| Q1 25 | $-0.77 | $-0.51 | ||
| Q4 24 | $-0.90 | $0.08 | ||
| Q3 24 | $-0.88 | $0.04 | ||
| Q2 24 | $-0.84 | $-0.04 | ||
| Q1 24 | $-0.94 | $-0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $378.2M | $767.2M |
| 总债务越低越好 | $1.5B | $1.1B |
| 股东权益账面价值 | $-99.3M | $1.1B |
| 总资产 | $2.0B | $3.8B |
| 负债/权益比越低杠杆越低 | — | 1.00× |
8季度趋势，按日历期对齐
现金及短期投资GHRDNT
| Q4 25 | $378.2M | $767.2M | ||
| Q3 25 | $580.0M | $804.7M | ||
| Q2 25 | $629.1M | $833.2M | ||
| Q1 25 | $698.6M | $717.3M | ||
| Q4 24 | $525.5M | $740.0M | ||
| Q3 24 | $585.0M | $748.9M | ||
| Q2 24 | $933.7M | $741.7M | ||
| Q1 24 | $1.0B | $527.0M |
总债务GHRDNT
| Q4 25 | $1.5B | $1.1B | ||
| Q3 25 | $1.1B | $1.1B | ||
| Q2 25 | $1.1B | $1.1B | ||
| Q1 25 | $1.1B | $1.0B | ||
| Q4 24 | $1.1B | $1.0B | ||
| Q3 24 | — | $1.0B | ||
| Q2 24 | — | $1.0B | ||
| Q1 24 | — | $834.6M |
股东权益GHRDNT
| Q4 25 | $-99.3M | $1.1B | ||
| Q3 25 | $-354.5M | $1.1B | ||
| Q2 25 | $-305.5M | $932.3M | ||
| Q1 25 | $-250.8M | $898.1M | ||
| Q4 24 | $-139.6M | $902.3M | ||
| Q3 24 | $-60.1M | $895.3M | ||
| Q2 24 | $-1.6M | $881.0M | ||
| Q1 24 | $68.3M | $873.0M |
总资产GHRDNT
| Q4 25 | $2.0B | $3.8B | ||
| Q3 25 | $1.3B | $3.7B | ||
| Q2 25 | $1.3B | $3.5B | ||
| Q1 25 | $1.3B | $3.3B | ||
| Q4 24 | $1.5B | $3.3B | ||
| Q3 24 | $1.5B | $3.3B | ||
| Q2 24 | $1.6B | $3.2B | ||
| Q1 24 | $1.7B | $3.0B |
负债/权益比GHRDNT
| Q4 25 | — | 1.00× | ||
| Q3 25 | — | 1.04× | ||
| Q2 25 | — | 1.18× | ||
| Q1 25 | — | 1.12× | ||
| Q4 24 | — | 1.13× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.17× | ||
| Q1 24 | — | 0.96× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-26.4M | $84.2M |
| 自由现金流经营现金流 - 资本支出 | $-54.2M | — |
| 自由现金流率自由现金流/营收 | -19.3% | — |
| 资本支出强度资本支出/营收 | 9.9% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-233.1M | — |
8季度趋势，按日历期对齐
经营现金流GHRDNT
| Q4 25 | $-26.4M | $84.2M | ||
| Q3 25 | $-35.4M | $52.8M | ||
| Q2 25 | $-60.3M | $120.3M | ||
| Q1 25 | $-62.7M | $41.5M | ||
| Q4 24 | $-64.5M | $42.5M | ||
| Q3 24 | $-51.1M | $57.4M | ||
| Q2 24 | $-94.0M | $116.0M | ||
| Q1 24 | $-30.3M | $17.1M |
自由现金流GHRDNT
| Q4 25 | $-54.2M | — | ||
| Q3 25 | $-45.8M | — | ||
| Q2 25 | $-65.9M | — | ||
| Q1 25 | $-67.1M | — | ||
| Q4 24 | $-83.4M | — | ||
| Q3 24 | $-55.3M | — | ||
| Q2 24 | $-99.1M | — | ||
| Q1 24 | $-37.2M | — |
自由现金流率GHRDNT
| Q4 25 | -19.3% | — | ||
| Q3 25 | -17.3% | — | ||
| Q2 25 | -28.4% | — | ||
| Q1 25 | -33.0% | — | ||
| Q4 24 | -41.3% | — | ||
| Q3 24 | -28.9% | — | ||
| Q2 24 | -55.9% | — | ||
| Q1 24 | -22.1% | — |
资本支出强度GHRDNT
| Q4 25 | 9.9% | — | ||
| Q3 25 | 3.9% | — | ||
| Q2 25 | 2.4% | — | ||
| Q1 25 | 2.2% | — | ||
| Q4 24 | 9.4% | — | ||
| Q3 24 | 2.2% | — | ||
| Q2 24 | 2.9% | — | ||
| Q1 24 | 4.1% | — |
现金转化率GHRDNT
| Q4 25 | — | — | ||
| Q3 25 | — | 9.75× | ||
| Q2 25 | — | 8.33× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 7.96× | ||
| Q3 24 | — | 17.89× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
RDNT
| Commercial Insurance1 | $301.0M | 55% |
| Medicare1 | $129.2M | 24% |
| Capitation Arrangements | $31.9M | 6% |
| Health Care Other | $20.4M | 4% |
| Digital Health | $16.4M | 3% |
| Other | $15.2M | 3% |
| Medicaid1 | $14.0M | 3% |
| Workers Compensation Personal Injury1 | $12.3M | 2% |
| Health Care Management Service | $7.5M | 1% |
